Intra-Cellular Therapies (ITCI) PT Raised to $47 at RBC Capital
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $47.00 (from $44.00) while maintaining a Outperform rating.
You May Also Be Interested In
- JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
- E Ink Holdings Inc (8069:TT) PT Lowered to NT$200 at Macquarie
- Alchip Technologies Ltd (3661:TT) PT Lowered to NT$5,300 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
